Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North…
? How to find High Confidence Swing Positions -> Stock Down due to a News/Catalyst -> That Bearish Catalyst Goes Away -> Look for Consolidation -> Trade the Bounce Back up $LQDA 30% Winner on Easy Swing Learn How https://t.co/0Ey6JavMwf
? Biotech Portfolio Update $LQDA idea i tweeted some time back is doing good on our Biotech Portfolio $VKTX position is down since adds but not worried long term , selling calls on its helping some with downside moves Check full biotech portfolio at tenetresearch…
$LQDA on my watchlist
@monaco_biotech $LQDA … up 50% on this news
$LQDA A $3.6B market cap wipeout versus a $380.7M settlement. That’s roughly a 9.5x disconnect between the market’s implied damage and the actual settlement cost. Do the math
$LQDA mentioned this a few days ago. It’s hard to think of many cases where an FDA-approved drug has been pulled off the market solely because of a judge’s ruling. A lot of FUD and worst-case theories circulating on X fueled uncertainty and contributed to a massive pullback in…
8 analysts rate LQDA Buy on consensus.
Consensus price target: $54.38 (+29.94% upside from $41.85)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Adair Jason Chief Business Officer | Oct 26, 2026 | Sale | 688 | $29.71K |
| Boyle Dana Chief Accounting Officer | Oct 26, 2026 | Sale | 1,581 | $68.28K |
| Bloch Stephen M director | Oct 5, 2026 | Sale | 235,477 | $6.39M |
| Krepp Sarah Chief Human Resource Officer | Sep 1, 2026 | Sale | 274 | $18.57K |
| Rielly-Gauvin Katherine director | Aug 20, 2026 | Sale | 18,393 | $1.33M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $158.32M | +1031.18% | $-68.92M |
| 2024 | $14M | -19.97% | $-130.39M |
| 2023 | $17.49M | +9.75% | $-78.5M |
Stock data for LQDA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics